Back to results
US 10,519,513 B2Granted
Cancer Biomarkers
AssigneeMyriad Genetics, Inc.
InventorsSteven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
Life of this patent
Estimating the term…
Abstract
Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
Claims8
A method for treating prostate cancer in a patient in need thereof, the method comprising:
- (1) obtaining a sample comprising prostate cancer tumor tissue from said patient;
- (2) determining the expression of a panel of genes comprising ASF1B, ASPM, BIRC5, BUB1B, C18orf24, CDC2, CDC20, CDCA3, CDCA8, CDKN3, CENPF, CENPM, CEP55, DLGAP5, DTL, FOXM1, KIAA0101, KIF11, KIF20A, MCM10, NUSAP1, ORC6L, PBK, PLK1, PRC1, PTTG1, RAD51, RAD54L, RRM2, TK1 and TOP2A in said sample comprising prostate cancer tumor tissue;
- (3) prognosing said patient as having a decreased likelihood of prostate cancer progression when the mean expression of the genes ASF1B, ASPM, BIRC5, BUB1B, C18orf24, CDC2, CDC20, CDCA3, CDCA8, CDKN3, CENPF, CENPM, CEP55, DLGAP5, DTL, FOXM1, KIAA0101, KIF11, KIF20A, MCM10, NUSAP1, ORC6L, PBK, PLK1, PRC1, PTTG1, RAD51, RAD54L, RRM2, TK1 and TOP2A is lower than a threshold index value;
- and
- (4) administering to said patient active surveillance based on the prognosis for a period of time until symptoms develop or there are signs that the cancer growth is accelerating;
- and
- (5) administering active treatment based on the developed symptoms or accelerated growth, wherein the active treatment is one or more of hormonal therapy, chemotherapy, radiation therapy and surgery.
4 more elements
A method for treating prostate cancer in a patient in need thereof, the method comprising:
- (1) obtaining a sample comprising prostate cancer tumor tissue from said patient;
- (2) determining the expression of a panel of genes comprising ASF1B, ASPM, BIRC5, BUB1B, C18orf24, CDC2, CDC20, CDCA3, CDCA8, CDKN3, CENPF, CENPM, CEP55, DLGAP5, DTL, FOXM1, KIAA0101, KIF11, KIF20A, MCM10, NUSAP1, ORC6L, PBK, PLK1, PRC1, PTTG1, RAD51, RAD54L, RRM2, TK1 and TOP2A in said sample comprising prostate cancer tumor tissue;
- (3) prognosing said patient as having an increased likelihood of prostate cancer progression when the mean expression of the genes ASF1B, ASPM, BIRC5, BUB1B, C18orf24, CDC2, CDC20, CDCA3, CDCA8, CDKN3, CENPF, CENPM, CEP55, DLGAP5, DTL, FOXM1, KIAA0101, KIF11, KIF20A, MCM10, NUSAP1, ORC6L, PBK, PLK1, PRC1, PTTG1, RAD51, RAD54L, RRM2, TK1 and TOP2A exceeds a threshold index value;
- and
- (4) administering to said patient one or more of hormonal therapy, chemotherapy, radiation therapy or surgery based on the prognosis.
2 more elements
Dependencies are inferred from the claim text.